Searchable abstracts of presentations at key conferences in endocrinology

ea0011oc8 | Signal transduction OC1 Novartis Oncology Young Investigator Award | ECE2006

Role of the calcium-calmodulin dependent kinase II in oncogenic Ras-induced proliferation

Cavallo AL , Illario M , Di Vito E , Monaco S , Fenzi G , Rossi G , Vitale M

Activation of the Ras/ERK pathway and stimulation of proliferation by integrins in thyroid cells requires CaMKII activation. To date, whether this role of CaMKII is a general mechanism or is restricted to integrin signalling is unknown. As oncogenic activation of the Ras/ERK pathway by mutated Ras, RET/PTC and Trk is frequent in papillary thyroid carcinoma (PTC), we investigated the expression and activation level of CaMKII in PTC primary culture and in stable cell lines.<...

ea0029p520 | Diabetes | ICEECE2012

Mesenchymal stem cells-derived microvesicles modulate cellular immune response to islet antigen GAD in type 1 diabetes.

Favaro E. , Deregibus M. , Camussi E. , Granata R. , Ghigo E. , Cavallo Perin P. , Zanone M. , Camussi G.

Background and aims: Mesenchymal stem cells (MSCs) exert an immunosuppressive effect on immune system and can abrogate in vitro the pro-inflammatory Th1 response to islet antigen GAD in type 1 diabetes by impairing the production of IFN-gamma. The mechanism may involve paracrine factors. Microvesicles (MVs) released from MSCs may account for this paracrine mechanism through a horizontal transfer of mRNA and microRNA. In the present study we evaluated whether MSC-derived...

ea0022p360 | Diabetes | ECE2010

Obestatin and ghrelin inhibit apoptosis of human pancreatic islet endothelial cells in high glucose culture

Favaro Enrica , Zanone Maria Maddalena , Miceli Ilaria , Settanni Fabio , Camussi Giovanni , Perin Paolo Cavallo , Ghigo Ezio , Granata Riccarda

Pancreatic islet microendothelium exhibits unique structural and functional features, in an interdependent physical and functional relationship with the neighbouring β-cells. Glucose toxicity is not solely restricted to β-cells, but affects also survival, proliferation of human pancreatic islet endothelial cells, thus possibly contributing to β-cell function impairment and β-cell loss. It has been previously demonstrated that the ghrelin gene derived peptid...

ea0022p661 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

SSTR5 ligand binding domain immunohistological detection in pituitary adenomas using Y-SSTR5 a new mouse monoclonal antibody

Rossi Valentina , Staibano Stefania , Del Basso De Caro Laura , Bellastella Giuseppe , Ilardi Gennaro , Cavallo Luigi , Colao Annamaria , Agostino Sinisi Antonio

Polyclonal antibodies against somatostatin receptors (SSTRs) available up to now recognizing intracellular sites of receptors and their recycling products do not detect bioactive ligand binding domains (LBDs) and are of limited performance in paraffin-embedded tissues. Aim of this study was to evaluate by immunohistochemistry the expression of SSTR5 on an archival series of pituitary tumors using a new MoAbs against the SST-binding domain (Y-SSTR5).Metho...

ea0049ep927 | Pituitary - Basic | ECE2017

Ketoconazole induces inhibition of cell viability and apoptosis in an ACTH-secreting tumour cell line model

Patalano Roberta , Pivonello Claudia , Solari Domenico , Vitulli Francesca , Iacuaniello Davide , Leo Monica De , Negri Mariarosaria , Provvisiero Donatella Paola , Cavallo Luigi Maria , Cappabianca Paolo , Colpo Annamaria , Pivonello Rosario

Chronic cortisol excess as a consequence of ACTH overproduction from a pituitary tumour is responsible for the development of Cushing’s disease (CD). The first-line treatment for CD is pituitary surgery, but medical treatment is an alternative second-line approach to control cortisol excess. Among pharmacological agents, the adrenal-blocking drug ketoconazole (KT), is able to control cortisol excess in the majority of patients with CD. During KT treatment, the adrenal blo...

ea0035oc6.2 | Bone, calcium &amp; vitamin D | ECE2014

High spontaneous osteoclastogenesis in pediatric osteogenesis imperfecta patients receiving or not intravenous neridronate

Faienza Maria Felicia , Tummolo Albina , Piacente Laura , Fiaschetto Rita , Ciccarelli Maria , Ventura Annamaria , Papadia Francesco , Colucci Silvia , Grano Maria , Cavallo Luciano , Brunetti Giacomina

Background: Osteogenesis imperfecta (OI) is a heritable disease of the connective tissues caused primarily by heterogeneous mutations in the genes encoding for type I collagen. Phenotypically, it is characterized by abnormal bone mineralization, tissue fragility, and skeletal deformities.Objective: The aim of this study was to investigate the osteoclastogenic potential of unfractionated peripheral blood mononuclear cells (PBMCs) from OI patients (mean ag...

ea0035p762 | Obesity | ECE2014

Higher serum levels of the Wnt-signaling antagonist DKK1 in obese respect to Prader–Willi syndrome

Brunetti Giacomina , Delvecchio Maurizio , Graziano Grugni , Ventura Annamaria , Ciccarelli Maria , Piacente Laura , Colucci Silvia , Cavallo Luciano , Grano Maria , Faienza Maria Felicia

Background: Obesity and in particular visceral adiposity has been related to low bone mineral density (BMD) and greater fracture risk. Subjects with Prader–Willi syndrome (PWS) have lower amount of visceral fat than patients with simple obesity, however can develop osteoporosis. A strong relationship between inhibition of the osteoblast formation and induction of the adipocyte differentiation has been demonstrated. Inhibitors of osteoblastogenesis, such as Dickkopf-1 (DKK...

ea0029p1379 | Pituitary Clinical | ICEECE2012

Epidemiology, histophatological characteristics and clinical manifestations of aggressive pituitary tumors, evaluated on the basis of KI-67 immunostaining: a single center experiense

Grasso L. , De Angelis M. , Di Somma C. , Savanelli C. , Galdiero M. , Cozzolino A. , Cavallo L. , Cappabianca P. , Del Basso De Caro M. , Pivonello R. , Colao A.

Aggressive pituitary tumors are classically defined as pituitary tumors with large size, rapid growth and massive invasion of surrounding anatomical structures. This is a group of pituitary tumors with biological behavior between pituitary adenomas and carcinomas and includes a new group of pituitary tumor, defined atypical adenoma, characterized by the presence of invasive growth and combination of increased mitotic activity and a Ki-67 labeling index >3%. The aim of this...

ea0026p289 | Pituitary | ECE2011

ACTH-secreting pituitary adenomas express higher SSTR5 than SSTR2 protein levels by immunohistochenistry using new monoclonal antibodies against SST-binding domains

Rossi V , Bellastella G , Staibano S , Ilardi G , Del Basso De Caro M L , Cavallo L , Cappabianca P , Abbondanza C , Colao A , Bellastella A , Sinisi A A

Pasireotide (SOM230), a somatostatin (SST) analogue targeting multiple SST receptors, is effective in reducing urinary free cortisol in patients with Cushing disease (CD), due to inoperable or recurrent ACTH secreting pituitary adenomas. The efficacy of SOM230 seems to be dependent on the presence of appropriate SSTRs, mainly SSTR2 and 5, on the membrane of tumor cells. Polyclonal antibodies available up to now recognizing cellular intracellular sites of receptors and their re...

ea0022p618 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Long term safety of recombinant human growth hormone (rhGH) in patients treated during childhood

Reimondo Giuseppe , Palmas Enrico , Vannelli Silvia , Bellone Jaele , Bellone Simonetta , Matarazzo Patrizia , Gasco Valentina , Borraccino Alberto , Migliaretti Giuseppe , Cavallo Franco , Ravaglia Aldo , Angeli Alberto , Aimaretti Gianluca , Terzolo Massimo

The potential side effects of the rhGH therapy have been evaluated only during treatment and the accessible databases have been developed as a post-marketing surveillance only by the Companies distributing rhGH. Aim of the present study was to evaluate health consequences (metabolic diseases and/or malignancies) in adults previously treated with rhGH during childhood. We recruited 284 patients (median age at diagnosis 12 years, range 3–17) who underwent rhGH treatment bet...